Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)
Data

Cancers·Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)

DataCancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)

Back to the Cancer of unknown primary, unfavourable hub →31 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

31

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
Microsatellite-unstable (MSI-high) gastric cancer
Shares Tumour-agnostic (tissue-agnostic) approval, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Nivolumab, Liquid biopsy (ctDNA) and the tag subtype-page.
Cancer
Mismatch-repair-deficient endometrial cancer
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Histopathology & immunohistochemistry, Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-page.
Cancer
POLE-ultramutated endometrial cancer
Shares Histopathology & immunohistochemistry, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab and the tag subtype-page.
Cancer
Stage IIB and IIC melanoma
Shares Nivolumab, Liquid biopsy (ctDNA), PD-1, Pembrolizumab and the tag subtype-page.
Cancer
p53-abnormal endometrial cancer, including uterine serous carcinoma
Shares Histopathology & immunohistochemistry, HER2, Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-page.
Cancer
Advanced and metastatic small bowel adenocarcinoma
Shares Tumour-agnostic (tissue-agnostic) approval, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), HER2, Comprehensive genomic profiling and the tag subtype-page.
Cancer
Acral melanoma
Shares BRAF, Nivolumab, PD-1, Pembrolizumab and the tag subtype-page.
Cancer
BRAF V600E-mutant colorectal cancer
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), BRAF, Nivolumab, Liquid biopsy (ctDNA) and the tag subtype-page.

technologies

Comprehensive genomic profiling Cytotoxic chemotherapy DNA methylation profiling Histopathology & immunohistochemistry Immune checkpoint inhibitors Liquid biopsy (ctDNA)PET/CT Platinum agents

targets

BRAF HER2 NTRK PD-1

drugs

ApprovedCytotoxic chemotherapy (platinum)

ApprovedCytotoxic regimen

Gemcitabine + cisplatin

ApprovedMonoclonal antibody (anti-PD-1)

Nivolumab · Opdivo / Opdivo Qvantig (SC)

ApprovedCytotoxic chemotherapy (taxane)

Paclitaxel / nab-paclitaxel · Taxol / Abraxane

ApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab · Keytruda / Keytruda Qlex (SC)

companies

Bristol Myers Squibb CSPC Pharmaceutical Group Merck & Co. (MSD)

terms

Immunohistochemistry (IHC)Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)Primary tumour Tumour mutational burden (TMB)Tumour-agnostic (tissue-agnostic) approval

trials

A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)CUPISCO

bottlenecks

Pain relief and palliative care are unavailable to most

key papers

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up CUPISCO: molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary Randomised phase 2 trial of site-specific treatment based on gene expression profiling versus carboplatin and paclitaxel in cancer of unknown primary

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-27 · Jude Gomila · Say what the cancer does, not how to feel about it · diff · file

Wikipedia

Cancer of unknown primary origin

Sources & links

CUPISCO (Lancet 2024)
ESMO CUP guideline 2023
Wikipedia

subtype-page site-agnostic

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/cup-unfavourable/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id cup-unfavourable.

WebMCP tools registered on this page: onco_search, onco_get_entity.